title: Varenicline-induced coronary thrombosis.
abstract: Varenicline (Champix, Chantix) has been available for use in smoking cessation since 2006. This drug has been associated with adverse cardiovascular events. Potential mechanisms for this association include modulation of parasymphathetic output from the brainstem to the heart, release of catecholamines and prothrombotic effect. We report the case of a 30-year-old man with no known cardiac disease, who developed thrombotic occlusion of left anterior descending artery and presented with acute coronary syndrome secondary to treatment with varenicline. The Naranjo probability scale indicates that varenicline was the probable cause of the myocardial infarction.
authors.affiliation: Cardiology Department, Kartal Kosuyolu Heart and Research Hospital, Istanbul, Turkey.
authors.forename: Arzu
authors.initials: A
authors.lastname: Kalayci
authors.forename: Aysegul
authors.initials: A
authors.lastname: Eren
authors.forename: Gonenc
authors.initials: G
authors.lastname: Kocabay
authors.forename: Can Yucel
authors.initials: CY
authors.lastname: Karabay
authors.forename: Cetin
authors.initials: C
authors.lastname: Gecmen
authors.forename: Cevat
authors.initials: C
authors.lastname: Kirma
mesh_terms: D000328:Adult; D001552:Benzazepines / Q000009:adverse effects*; D003328:Coronary Thrombosis / Q000139:chemically induced*; D006801:Humans; D008297:Male; D018722:Nicotinic Agonists / Q000009:adverse effects*; D011810:Quinoxalines / Q000009:adverse effects*; D016540:Smoking Cessation; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline
keywords: acute coronary syndrome; coronary thrombosis; varenicline